Mon panier

Biotinylated Cynomolgus LAG-3 / CD223 Protein, Mouse IgG2a Fc Tag, ultra sensitivity (primary amine labeling) (MALS verified)

Avis des utilisateurs
Numéro de produit/spécification
Prix
Qté
LA3-C8258-25ug
$360.00
LA3-C8258-200ug
$1565.00
ETA of in-stock products:2 business days
Total des articles Montant du produit$ 0

Détails du produit

  • Synonyms

    LAG3, CD223, FDC

  • Source

    Biotinylated Cynomolgus LAG-3, Mouse IgG2a Fc Tag, primary amine labeling (LA3-C8258) is expressed from human 293 cells (HEK293). It contains AA Ala 18 - His 449 (Accession # XP_005570011.1). It is the biotinylated form of Cynomolgus LAG-3, Mouse IgG2a Fc tag (Cat. No. LA3-C52A0).

    Predicted N-terminus: Ala 18

    Request for sequence
  • Molecular Characterization

    LAG-3 Structure

    Other Tags and Version Biotin & Other Labeled Version

    This protein carries a mouse IgG2a Fc tag at the C-terminus.

    The protein has a calculated MW of 73.5 kDa. The protein migrates as 80-90 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Labeling

    The primary amines in the side chains of lysine residues and the N-terminus of the protein are conjugated with biotins using standard chemical labeling method. A standard biotin reagent (13.5 angstroms) is used in this product.

  • Protein Ratio

    Passed as determined by the HABA assay / binding ELISA.

  • Purity

    >95% as determined by SDS-PAGE.

    >95% as determined by SEC-MALS.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Shipping and Storage

    This product is shipped at ambient temperature.

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Les clients ont également consulté

Affichage des données

  • SDS-PAGE

    LAG-3 SDS-PAGE

    Biotinylated Cynomolgus LAG-3, Mouse IgG2a Fc Tag, primary amine labeling on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

  • SEC-MALS

    LAG-3 SEC-MALS

    The purity of Biotinylated Cynomolgus LAG-3, Mouse IgG2a Fc Tag, primary amine labeling (Cat. No. LA3-C8258) is more than 95% and the molecular weight of this protein is around 165-210 kDa verified by SEC-MALS.

    Report
  • Bioactivity-ELISA

     LAG-3 ELISA

    Immobilized Biotinylated Cynomolgus LAG-3, Mouse IgG2a Fc Tag, primary amine labeling (Cat. No. LA3-C8258) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Monoclonal Anti-Human LAG3 Antibody, Human IgG1 with a linear range of 0.2-6 ng/mL (QC tested).

    Protocol

Avis des utilisateurs
Publier un commentaire

Introduction de fond

Lymphocyte activation gene 3 protein (LAG3) is also known as CD antigen CD223 and protein FDC, which belongs to immunoglobulin (Ig) superfamily and contains 4 extracellular Ig-like domains. The LAG3 gene contains 8 exons. The sequence data, exon/intron organization, and chromosomal localization all indicate a close relationship of LAG3 to CD4. LAG3 /CD223 involved in lymphocyte activation. LAG3 /CD223 binds to HLA class-II antigens.

Progrès de frontière

 
Progrès du développement médicamenteux
  • Nom anglais:

    Lymphocyte activation gene 3 protein

  • Catégorie:

  • Nombre de médicaments répertoriés:

    1 Détails

  • Nombre de médicaments cliniques:

    32 Détails

  • Étape de développement la plus élevée:

    Approved

Drug Candidate Licensing
More
  • Informations de base sur le produit
  • Détails du produit
  • Les clients ont également consulté
  • Affichage des données
  • Avis des utilisateurs
  • Contexte